| Literature DB >> 28923389 |
Yi-Min Liu1, Wei-Chun HuangFu2, Han-Li Huang2, Wei-Cheng Wu1, Yi-Lin Chen2, Yun Yen2, Hsiang-Ling Huang1, Chih-Ying Nien1, Mei-Jung Lai3, Shiow-Lin Pan4, Jing-Ping Liou5.
Abstract
A series of 1,4-naphthoquinones (10a-10q) were synthesized and evaluated for anticancer activity. Compound 10e was identified as an inhibitor of Itch, a HECT domain-E3 ligase. In an evaluation of in vivo efficacy, 10e exhibited remarkable anticancer activity with TGI values of 98.3% and 100% at 25 mg/kg and 50 mg/kg orally daily, respectively, against human RPMI-8226 multiple myeloma xenograft. Treatment with 10e also showed a decrease of Itch level in human RPMI-8226 multiple myeloma cells. Thus 10e is a lead compound for further development of inhibitors targeting E3 ligase for treatment of multiple myeloma.Entities:
Keywords: HECT domain E3 ligase inhibitor; Naphthoquinone
Mesh:
Substances:
Year: 2017 PMID: 28923389 DOI: 10.1016/j.ejmech.2017.09.011
Source DB: PubMed Journal: Eur J Med Chem ISSN: 0223-5234 Impact factor: 6.514